Trial reportBritish journal of cancer2016
The utility of urine-circulating miRNAs for detection of prostate cancer.
Trial report in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 5 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Diagnostic Value of microRNA-375 as Future Biomarker for Prostate Cancer Detection: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2022Pooled it
- MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data.British journal of cancer · 2022Pooled it
- Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis.Bioscience reports · 2022Pooled it
- Urinary microRNAs expression in prostate cancer diagnosis: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Pooled it
- The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.Journal of cellular biochemistry · 2018Pooled it
- Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.The Prostate · 2018Trial
- Exploratory Small RNA Sequencing in Localized Versus Locally Advanced Prostate Cancer: Putative Roles of CLTC and CDK6 as Downstream Targets of Differentially Expressed MicroRNAs.Pharmaceuticals (Basel, Switzerland) · 2026Article
- MiRNA based liquid biopsy for castration-resistant prostate cancer diagnostics.Molecular and cellular biochemistry · 2026Article
- Pilot study of dual-arm absolute quantification of miR-130a and miR-365a in plasma and urine reveals 3p/5p strand-ratio shifts in prostate cancer.Scientific reports · 2026Article
- Epigenetic and Liquid Biopsy Biomarkers in Prostate Cancer: Bridging Tumor Heterogeneity and Clinical Implementation.Cancers · 2026Review
- Oligonucleotide surface attachment by tosylation for digital detection of microRNA using photonic resonator absorption microscopy.APL bioengineering · 2025Article
- Comprehensive computational analysis of differentially expressed miRNAs and their influence on transcriptomic signatures in prostate cancer.Scientific reports · 2025Article
- Role of MicroRNA-21 in Prostate Cancer Progression and Metastasis: Molecular Mechanisms to Therapeutic Targets.Annals of surgical oncology · 2024Review
- Evaluation of miR-148a-3p and miR-106a-5p as Biomarkers for Prostate Cancer: Pilot Study.Genes · 2024Article
- Extracellular miRNAs in the serum and feces of mice exposed to high‑dose radiation.Biomedical reports · 2024Article
- Urinary miRNAs: Technical Updates.MicroRNA (Shariqah, United Arab Emirates) · 2024Review
- Clinical Biofluid Assays for Prostate Cancer.Cancers · 2023Review
- Design of a printed electrochemical strip towards miRNA-21 detection in urine samples: optimization of the experimental procedures for real sample application.Analytical and bioanalytical chemistry · 2023Article
- Using Small Non-Coding RNAs in Extracellular Vesicles of Semen as Biomarkers of Male Reproductive System Health: Opportunities and Challenges.International journal of molecular sciences · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this paper, the utility of urine-circulating microRNAs (miRNAs) as the potential biomarker of prostate cancer (PCa), the second most prevalent male cancer worldwide, was evaluated.
methodsCancerous (N=56) and non-cancerous (N=16) prostate tissues were analysed on TaqMan Low Density Array, with the initial screening of 754 miRNAs in a subset of the samples. The abundance of selected miRNAs was analysed in urine specimens from two independent cohorts of patients with PCa (N=215 overall), benign prostatic hyperplasia (BPH; N=23), and asymptomatic controls (ASC; N=62) by means of quantitative reverse transcription PCR.
resultsOver 100 miRNAs were found deregulated in PCa as compared with non-cancerous prostate tissue. After thorough validation, four miRNAs were selected for the analysis in urine specimens. The abundance of miR-148a and miR-375 in urine was identified as specific biomarkers of PCa in both cohorts. Combined analysis of urine-circulating miR-148a and miR-375 was highly sensitive and specific for PCa in both cohorts (AUC=0.79 and 0.84) and strongly improved the diagnostic power of the PSA test (AUC=0.85, cohort PCa1), including the grey diagnostic zone (AUC=0.90).
conclusionsQuantitative measurement of urine-circulating miR-148a and miR-375 can serve as the non-invasive tool for sensitive and specific detection of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.